New combo therapy targets Hard-to-Treat prostate cancer
NCT ID NCT07316686
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a combination of two drugs—docetaxel (chemotherapy) and a radioactive compound called 177Lu-PSMA-I&T—in men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to find the safest dose of docetaxel when used with the radioactive drug. Only 18 men will take part, and the study focuses on side effects and tolerability, not yet on how well the treatment works against the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
docetaxel and 177Lu-PSMA-I&T (a radioactive drug that targets prostate cancer cells)
What this could lead to
If this works, it could point toward a more effective first-line treatment for advanced prostate cancer that has stopped responding to hormone therapy.
What could go wrong
This is a very early Phase I trial with only 18 participants, so it is primarily testing safety and dosing. It is too small to prove whether the combination actually improves outcomes, and side effects from the chemotherapy and radiation could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER (ADENOCARCINOMA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Instituto do Câncer do Estado de São Paulo - ICESP
São Paulo, 01246000, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••